Oct. 17, 2024 — With viral outbreaks spreading more quickly, faster responses and quicker development of new vaccines has become crucial. However, production of the mRNA used in vaccines is ...

IGA score of cleared (0) or minimal disease (1) was achieved by a significantly greater proportion of those in the guselkumab vs placebo group, 74.2% vs 12.4%, respectively. Arexvy is currently ...

"We are pleased to announce positive head-to-head clinical data for our non-adjuvanted SCB-1019 RSV vaccine candidate compared to AS01E-adjuvanted AREXVY, indicating our potential best-in-class ...

I-Mab, a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will ...

Synechron, Inc., a leading global digital transformation consulting firm, announced today that it has acquired Cloobees, an award winning, top-tier Salesforce implementation partner. Cloobees will add ...

GSK is scheduled to report results for the third quarter on Wednesday. Here is what to know. TURNOVER FORECAST: The British pharmaceutical giant is expected to report turnover of 8.00 billion ...

The 2023 approval of the world’s first RSV vaccines in the US and Europe, GSK’s AREXVY and Pfizer’s ABRYSVO, was a significant milestone in addressing the grave unmet medical needs associated with RSV ...

Preliminary data were announced from 2 clinical trials evaluating Arexvy (respiratory syncytial virus [RSV] vaccine, adjuvanted) in a broader population of adults at increased for RSV disease. Arexvy ...

The company has important products such as Shingrix and Arexvy in its vaccine segment ... like Trelegy for asthma and chronic obstructive pulmonary disease [COPD]. Trelegy is a one-dose daily ...

On Aug. 22, the Food and Drug Administration approved and authorized newer formulations of the two mRNA vaccines, from Pfizer/BioNTech and Moderna, for ages 6 months and up. About a week later ...

GSK plc announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted ... such as chronic obstructive pulmonary disease (COPD), asthma, heart failure and ...